<DOC>
	<DOC>NCT00567268</DOC>
	<brief_summary>The objective of the this surveillance is to collect information about 1)adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Drug Use Investigation Of Gabapentin</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Gabapentin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients need to be taking Gabapentin in order to be enrolled in the surveillance Patients not taking Gabapentin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Post-Marketing surveillance</keyword>
</DOC>